The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.

The AVG’s specific objectives are to promote understanding of the use of antivirals and other therapeutic strategies (antibodies, immunomodulators, drug combinations, etc) against respiratory virus infections. The group collates and provides up to date information and communicates expert commentary on the emergence of antiviral resistance as well as on preclinical and clinical development of potential novel/new therapeutics.

Principal activities and areas of interest of the AVG are listed under members’ interests.

 

AVG COMMITTEE

The AVG committee co-ordinates the various activities and represent the interests of the isirv-AVG. Its composition reflects the range of interests and activities of the AVG and is geographically representative of its membership. Committee members have responsibility for organizing particular activities of the group and collating information on particular subject areas for the website or publication, and integrating contributions from the AVG membership.
 

Members are elected, initially for a period of three years. The procedure and rules for electing new members to the committee are consistent with those adopted for election to the isirv Council. Additional Members may be co-opted from the general AVG membership to serve on the Executive Committee to ensure a balance of geography, gender, scientific interests and skills.

 

Members will participate in an Annual Committee Meeting, typically held during an AVG-sponsored meeting. Members also participate in conference calls to generate ideas for AVG meetings/workshops, to advise on publications and other initiatives for scientific exchange, as well as to promote the activities of the Group, and isirv as a whole.
 

Committee members:

	Kimberly Armstrong	Biomedical Advanced Research and Development Authority (BARDA), USA
	Karoline Bragstad	National Influenza Centre, Oslo, Norway
	Bin Cao	Capital Medical University, Beijing, China
	Shikha Garg	Centers for Disease Control and Prevention, Atlanta, USA.
	Elena Govorkova	St Jude Children's Research Hospital, Memphis, USA
	Larisa Gubareva	Centers for Disease Control and Prevention, Atlanta, USA
	Alan Hay	Former Director of the WHO Collaborating Centre for Reference and Research on Influenza, London, UK AVG Past-Chair
	Frederick Hayden	University of Virginia School of Medicine, Charlottesville, USA
	Michael Ison	Division of Microbiology and Infectious Diseases (DMID/NIAID/NIH) CHAIR
	Angie Lackenby	Public Health England, London, UK
	Robert Krug	University of Texas at Austin, Austin, USA
	Jenny McKimm-Breschkin	Melbourne, Australia
	Lieve Naesens	The Rega Institute, Leuven, Belgium
	Andrés Pizzorno	International Center for Research in Infectious Diseases, Lyon, France Co-Chair
	Nahoko Shindo	World Health Organisation, Geneva, Switzerland
	Norio Sugaya	Keiyu Hospital, Yokohama, Japan
	Emi Takashita	National Institute of Infectious Diseases, Tokyo, Japan.
	Sylvie van der Werf	Institut Pasteur, Paris, France
	Hui-Ling Yen	University of HongKong, Hongkong SAR, China

 

top of page